Maze Therapeutics (NASDAQ:MAZE) Lowered to “Sell” Rating by Wall Street Zen

Maze Therapeutics (NASDAQ:MAZE) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Raymond James Financial began coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective for the company. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a report on Wednesday, January 28th. Wells Fargo & Company started coverage on Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Friday, December 19th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Stock Up 2.5%

Shares of NASDAQ MAZE opened at $45.03 on Friday. The firm has a 50-day simple moving average of $41.74 and a 200-day simple moving average of $30.01. The stock has a market capitalization of $2.17 billion and a price-to-earnings ratio of -2.15. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $49.25.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $426,001.68. This represents a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 200,000 shares of company stock worth $8,254,792.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. lifted its position in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Maze Therapeutics by 27.1% during the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after acquiring an additional 362,060 shares during the period. Woodline Partners LP boosted its position in shares of Maze Therapeutics by 10.0% in the third quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after acquiring an additional 94,529 shares during the last quarter. Marshall Wace LLP grew its holdings in Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after purchasing an additional 758,104 shares during the period. Finally, ArrowMark Colorado Holdings LLC acquired a new position in Maze Therapeutics during the third quarter worth approximately $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.